WallStreetZenWallStreetZen

NASDAQ: NRIX
Nurix Therapeutics Inc Stock

$22.10+1.32 (+6.35%)
Updated Jul 22, 2024
NRIX Price
$22.10
Fair Value Price
N/A
Market Cap
$1.42B
52 Week Low
$4.22
52 Week High
$24.38
P/E
-7.57x
P/B
3.84x
P/S
15.77x
PEG
N/A
Dividend Yield
N/A
Revenue
$62.30M
Earnings
-$165.00M
Gross Margin
100%
Operating Margin
-264.55%
Profit Margin
-264.8%
Debt to Equity
0.38
Operating Cash Flow
-$96M
Beta
1.58
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

NRIX Overview

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NRIX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NRIX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NRIX is good value based on its book value relative to its share price (3.84x), compared to the US Biotechnology industry average (6.3x)
P/B vs Industry Valuation
NRIX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NRIX due diligence checks available for Premium users.

Be the first to know about important NRIX news, forecast changes, insider trades & much more!

NRIX News

Valuation

NRIX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-7.57x
Industry
-27.86x
Market
29.85x

NRIX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.84x
Industry
6.3x
NRIX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NRIX's financial health

Profit margin

Revenue
$12.1M
Net Income
-$44.5M
Profit Margin
-368.4%
NRIX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NRIX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$511.0M
Liabilities
$140.3M
Debt to equity
0.38
NRIX's short-term assets ($450.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NRIX's short-term assets ($450.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NRIX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$39.7M
Investing
-$131.1M
Financing
$237.8M
NRIX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NRIX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
NRIX$1.42B+6.35%-7.57x3.84x
LBPH$1.43B+2.31%-16.42x4.56x
BLTE$1.46B-0.79%-41.96x16.09x
VIR$1.38B+1.20%-2.53x0.89x
SANA$1.35B+5.34%-3.99x3.61x

Nurix Therapeutics Stock FAQ

What is Nurix Therapeutics's quote symbol?

(NASDAQ: NRIX) Nurix Therapeutics trades on the NASDAQ under the ticker symbol NRIX. Nurix Therapeutics stock quotes can also be displayed as NASDAQ: NRIX.

If you're new to stock investing, here's how to buy Nurix Therapeutics stock.

What is the 52 week high and low for Nurix Therapeutics (NASDAQ: NRIX)?

(NASDAQ: NRIX) Nurix Therapeutics's 52-week high was $24.38, and its 52-week low was $4.22. It is currently -9.34% from its 52-week high and 423.7% from its 52-week low.

How much is Nurix Therapeutics stock worth today?

(NASDAQ: NRIX) Nurix Therapeutics currently has 64,411,870 outstanding shares. With Nurix Therapeutics stock trading at $22.10 per share, the total value of Nurix Therapeutics stock (market capitalization) is $1.42B.

Nurix Therapeutics stock was originally listed at a price of $19.01 in Jul 24, 2020. If you had invested in Nurix Therapeutics stock at $19.01, your return over the last 3 years would have been 16.25%, for an annualized return of 5.15% (not including any dividends or dividend reinvestments).

How much is Nurix Therapeutics's stock price per share?

(NASDAQ: NRIX) Nurix Therapeutics stock price per share is $22.10 today (as of Jul 22, 2024).

What is Nurix Therapeutics's Market Cap?

(NASDAQ: NRIX) Nurix Therapeutics's market cap is $1.42B, as of Jul 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Nurix Therapeutics's market cap is calculated by multiplying NRIX's current stock price of $22.10 by NRIX's total outstanding shares of 64,411,870.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.